1. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
- Author
-
García-Sanz R, González-López TJ, Vázquez L, Hermida G, Graciani IF, and San Miguel JF
- Subjects
- Adult, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bleomycin administration & dosage, Carmustine administration & dosage, Cisplatin administration & dosage, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Dacarbazine administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Drug Resistance, Neoplasm, Etoposide administration & dosage, Hodgkin Disease radiotherapy, Hodgkin Disease surgery, Humans, Male, Mechlorethamine administration & dosage, Melphalan administration & dosage, Organoplatinum Compounds administration & dosage, Paclitaxel administration & dosage, Peripheral Blood Stem Cell Transplantation, Prednisolone administration & dosage, Prednisone administration & dosage, Procarbazine administration & dosage, Remission Induction, Rituximab, Thalidomide administration & dosage, Topotecan administration & dosage, Transplantation, Autologous, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Vinblastine administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy, Salvage Therapy
- Abstract
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report two highly refractory patients with HL who successfully responded to a combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex). Despite the use of a very large number of different drugs (>5 different schemes) including high-dose therapy and autologous and allogeneic stem cell transplantation, both patients proved to be suffering from a highly resistant disease. Fortunately, they finally responded to the ThaCyDex combination, achieving sustained complete remission that would support the running of a trial within this setting.
- Published
- 2010
- Full Text
- View/download PDF